The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | ESMO 2018 Congress

Colorectal Cancer MORE >>

According to findings from the first neoadjuvant study to test ipilimumab (Yervoy) plus nivolumab (Opdivo) in early-stage mismatch repair deficient tumors and MMR proficient colon cancers, the combination induced major pathologic responses from all 7 patients with dMMR tumors. 

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.